 | • レポートコード：MRC2303B129 • 出版社/出版日：Mordor Intelligence / 2023年3月 • レポート形態：英文、PDF、152ページ • 納品方法：Eメール（受注後2-3営業日） • 産業分類：医療 |
| Single User | ￥712,500 (USD4,750) | ▷ お問い合わせ |
| Corporate License | ￥1,312,500 (USD8,750) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| モルドールインテリジェンス社の市場調査書では、2021年に596.61百万ドルであった世界の敗血症診断市場規模が、予測期間中に年平均7.74％上昇すると推測されています。本調査書では、敗血症診断の世界市場を広く調査・分析をし、イントロダクション、調査手法、エグゼクティブサマリー、市場動向、技術別（分子診断法、マイクロバイオロジー法、イムノアッセイ、その他）分析、製品別（器具、アッセイ・試薬、その他）分析、診断方法別（従来式診断、自動式診断）分析、病原菌別（細菌性敗血症、真菌性敗血症、その他）分析、地域別（アメリカ、カナダ、メキシコ、ドイツ、イギリス、フランス、イタリア、スペイン、中国、日本、インド、オーストラリア、韓国、中東、南アフリカ、ブラジル、アルゼンチン）分析、競争状況、市場機会・将来動向などを整理しています。また、本書には、Abbott Laboratories Inc.、Axis-Shield Diagnostics Ltd、Becton, Dickinson, and Company、BioMerieux SA、Bruker Corporation、Cube Dx GmbH、Danaher Corporation、EKF Diagnosticsなどの企業情報が含まれています。 ・イントロダクション ・調査手法 ・エグゼクティブサマリー ・市場動向 ・世界の敗血症診断市場規模：技術別 - 分子診断法敗血症診断の市場規模 - マイクロバイオロジー法敗血症診断の市場規模 - イムノアッセイの市場規模 - その他敗血症診断の市場規模 ・世界の敗血症診断市場規模：製品別 - 器具の市場規模 - アッセイ・試薬の市場規模 - その他敗血症診断の市場規模 ・世界の敗血症診断市場規模：診断方法別 - 従来式診断における市場規模 - 自動式診断における市場規模 ・世界の敗血症診断市場規模：病原菌別 - 細菌性敗血症における市場規模 - 真菌性敗血症における市場規模 - その他病原菌における市場規模 ・世界の敗血症診断市場規模：地域別 - 北米の敗血症診断市場規模 アメリカの敗血症診断市場規模 カナダの敗血症診断市場規模 メキシコの敗血症診断市場規模 … - ヨーロッパの敗血症診断市場規模 ドイツの敗血症診断市場規模 イギリスの敗血症診断市場規模 フランスの敗血症診断市場規模 … - アジア太平洋の敗血症診断市場規模 中国の敗血症診断市場規模 日本の敗血症診断市場規模 インドの敗血症診断市場規模 … - 南米/中東の敗血症診断市場規模 南アフリカの敗血症診断市場規模 ブラジルの敗血症診断市場規模 アルゼンチンの敗血症診断市場規模 … ・競争状況 ・市場機会・将来動向 |
The sepsis diagnostics market was valued at USD 596.61 million in 2021, registering a CAGR of 7.74% during the forecast period.
Increasing incidences of sepsis in COVID-19 patients is anticipated to have a positive impact on the market studied. For instance, according to a report published by the Centers for Disease Control and Prevention (CDC) in 2021, “2020 National and State Healthcare-Associated Infections Progress Report”, the analysis of the 2020 acute care hospitals standardized infection ratios found significant increases in central line-associated bloodstream infections, catheter-associated urinary tract infections, ventilator-associated events, and methicillin-resistant Staphylococcus aureus bacteremia compared to 2019. The largest increases occurred during quarter 4 of 2020. Furthermore, according to a study published by PLOS in August 2021, “Immunometabolic signatures predict the risk of progression to sepsis in COVID-19,” COVID-19 patients are at the highest risk of developing sepsis. Hence, this is expected to create new opportunities for novel diagnosis in the market studied.
The major factors for the growth of the sepsis diagnostics market include the increasing burden of sepsis, the growing burden of hospital-acquired infections, the increasing number of pneumonia cases, the rise in the number of sepsis procedures, and an increase in funding for sepsis-related research activities. Hospital-acquired infections (HAIs) are the most common complications among hospitalized patients. For instance, according to a report published by the Centers for Disease Control and Prevention (CDC) in 2021, “2020 National and State Healthcare-Associated Infections Progress Report”, about 24%, 35%, and 15% increase in central line-associated bloodstream infections, ventilator-associated events, and Methicillin-resistant Staphylococcus Aureus (MRSA) bacteremia between 2019 and 2020 in the United States. The rising bloodstream infections will lead to increased adoption of sepsis diagnostic products. Additionally, in June 2021, the collaboration led by the University of Liverpool has received more than GBP 3 million in funding for a new intervention that will actively prevent, treat and evaluate maternal sepsis.
Thus, the rise in the prevalence of sepsis and increase in funding for research activities for sepsis diagnosis are expected to drive the overall growth of the sepsis diagnosis market over the forecast period.
Sepsis Diagnostics Market Trends
The Molecular Diagnostics Segment Has a Significant Share in the Market
Sepsis affects significant patient populations in hospitals and is the sixth most common reason for hospitalization. Rapid and accurate profiling of infection-causing pathogens remains a significant challenge in modern healthcare. Moreover, identification of the causative pathogen is essential in selecting appropriate antibiotic therapy as part of the treatment. These requirements make molecular diagnostics (MDx) an attractive approach to consider for sepsis diagnostics.
Molecular diagnostics have attracted several multinational companies and institutions, owing to their easy feasibility and accuracy in detection methods. The blood culture analysis for rapid and accurate profiling of infections has been the gold standard for the molecular diagnostic method. However, the cost of molecular diagnostics has remained very high, as compared to conventional procedures, which restricts its market growth. Several companies are investing in point-of-care molecular diagnostics for the early diagnosis of bacterial and viral pathogens and better patient management. For instance, in October 2020, Immunexpress launched a rapid SeptiCyte, a one-hour molecular diagnostic test for sepsis in Europe on Biocartis’ Idylla platform. This is one of the first rapid, fully-integrated, and immune response-based tests to aid clinicians with a sepsis diagnosis.
Furthermore, researchers are attempting to develop a molecular diagnostic that can detect the COVID-19 and sepsis, as well as discriminate between the two. In November 2020, the Hellenic Institute for the Study of Sepsis and, in part by Sanmina Corporation, funded a study and developed a novel optical biosensor for the early diagnosis of sepsis and severe COVID-19. These developments are expected to have a positive impact on the growth of this segment.
North America is Expected to Hold a Large Share of the Market
North America is found to hold a major share of the sepsis diagnostics market and is expected to show a similar trend over the forecast period, without significant fluctuations. According to the Centers for Disease Control and Prevention, in August 2021, approximately 1.7 million adults in America develop sepsis, and nearly 270,000 Americans die due to sepsis. It was also found that 1 in 3 patients who die in a hospital has sepsis. Thus, the high incidence rate of the disease in the country will boost its diagnosis, thus, boosting the market.
Moreover, rising investments in the fields of research and development for the diagnosis of sepsis will also boost the market. For instance, in April 2020, Cytovale Inc. expanded its partnership with the Biomedical Advanced Research and Development Authority (BARDA) for diagnosing sepsis in patients with potential respiratory infections, including COVID-19. The research is estimated to stand at the cost of USD 5.9 million, with approximately USD 3.83 contributed by the Biomedical Advanced Research and Development Authority (BARDA), thus, driving the market.
Therefore, the rising prevalence of sepsis and increasing investments in the research and development of sepsis diagnosis may augment the growth of the market in the United States.
Sepsis Diagnostics Market Competitor Analysis
The sepsis diagnostics market is moderately consolidated owing to the presence of a few key players. The market is expected to drive due to the products launched by the key players in the market and the rise in research initiatives on sepsis diagnostics by the key players. Some of the market players are Abbott, Becton, Dickinson, and Company, bioMérieux SA, Bruker Corporation, F. Hoffmann-LA Roche Ltd, and Immunexpress Inc., among others.
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
1 INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Burden of Sepsis
4.2.2 Growing Incidence of Hospital-acquired Infections
4.2.3 Rise in the Number of Sepsis Procedures and Increase in Funding for Sepsis-related Research Activities
4.3 Market Restraints
4.3.1 High Cost of Automated Diagnostic Instruments
4.3.2 Lack of Well-established Reimbursement Policies for Sepsis
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION (Market Size by Value – USD million)
5.1 By Technology
5.1.1 Molecular Diagnostics
5.1.2 Microbiology
5.1.3 Immunoassay
5.1.4 Other Technologies
5.2 By Product
5.2.1 Instruments
5.2.2 Assays and Reagents
5.2.3 Other Products
5.3 By Diagnostic Method
5.3.1 Conventional Diagnostics
5.3.2 Automated Diagnostics
5.4 By Pathogen
5.4.1 Bacterial Sepsis
5.4.2 Fungal Sepsis
5.4.3 Other Pathogens
5.5 By Geography
5.5.1 North America
5.5.1.1 United States
5.5.1.2 Canada
5.5.1.3 Mexico
5.5.2 Europe
5.5.2.1 Germany
5.5.2.2 United Kingdom
5.5.2.3 France
5.5.2.4 Italy
5.5.2.5 Spain
5.5.2.6 Rest of Europe
5.5.3 Asia-Pacific
5.5.3.1 China
5.5.3.2 Japan
5.5.3.3 India
5.5.3.4 Australia
5.5.3.5 South Korea
5.5.3.6 Rest of Asia-Pacific
5.5.4 Middle-East
5.5.4.1 GCC
5.5.4.2 South Africa
5.5.4.3 Rest of Middle-East
5.5.5 South America
5.5.5.1 Brazil
5.5.5.2 Argentina
5.5.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Abbott Laboratories Inc.
6.1.2 Axis-Shield Diagnostics Ltd
6.1.3 Becton, Dickinson, and Company
6.1.4 BioMerieux SA
6.1.5 Bruker Corporation
6.1.6 Cube Dx GmbH
6.1.7 Danaher Corporation
6.1.8 EKF Diagnostics
6.1.9 F. Hoffmann-LA Roche Ltd
6.1.10 Immunexpress Inc.
6.1.11 Diasorin
6.1.12 Response Biomedical Corp.
6.1.13 Sysmex Corporation
6.1.14 T2 Biosystems Inc.
6.1.15 Thermo Fisher Scientific
7 MARKET OPPORTUNITIES AND FUTURE TRENDS